Purab Pal

Dr. Purab Pal

University of Illinois at Chicago, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PPPurab Pal
Purab Pal
GAG. Ekin Atilla-Gokcumen
G. Ekin Atilla-Gokcumen
JFJonna Frasor
Jonna Frasor
One of the classic hallmarks of cancer is the imbalance between elevated cell proliferation and reduced cell death. Ceramide, a bioactive sphingolipid that can regulate this balance, has long been implicated in cancer. While the effects of ceramide on cell death and therapeutic efficacy are well established, emerging evidence indicates that ceramide turnover to downstream sphingolipids, such as sphingomyelin, hexosylceramides, sphingosine-1-phosphate, and ceramide-1-phosphate, is equally important in driving pro-tumorigenic phenotypes, such as proliferation, survival, migration, stemness, and therapy resistance. The complex and dynamic sphingolipid network has been extensively studied in several cancers, including breast cancer, to find key sphingolipidomic alterations that can be exploited to develop new therapeutic strategies to improve patient outcomes. Here, we review how the current literature shapes our understanding of how ceramide synthesis and turnover are altered in breast cancer and how these changes offer potential strategies to improve breast cancer therapy.

12 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PPPurab Pal
Purab Pal
AMAlec Millner
Alec Millner
SSSvetlana E. Semina
Svetlana E. Semina
RHRosemary J. Huggins
Rosemary J. Huggins
LRLogan Running
Logan Running
JFJonna Frasor
Jonna Frasor
ET resistance is a critical problem for estrogen receptor-positive (ER+) breast cancer. In this study, we have investigated how alterations in sphingolipids promote cell survival in ET-resistant breast cancer. We have performed LC-MS-based targeted sphingolipidomics of tamoxifen-sensitive and -resistant MCF-7 breast cancer cell lines. Follow-up studies included treatments of cell lines and patient-derived xenograft organoids (PDxO) with small molecule inhibitors; cytometric analyses to measure cell death, proliferation, and apoptosis; siRNA-mediated knockdown; RT-qPCR and Western blot for gene and protein expression; targeted lipid analysis; and lipid addback experiments. We found that tamoxifen-resistant cells have lower levels of ceramides and hexosylceramides compared to their tamoxifen-sensitive counterpart. Upon perturbing the sphingolipid pathway with small molecule inhibitors of key enzymes, we identified that CERK is essential for tamoxifen-resistant breast cancer cell survival, as well as a fulvestrant-resistant PDxO. CERK inhibition induces ceramide-mediated cell death in tamoxifen-resistant cells. Ceramide-1-phosphate (C1P) partially reverses CERK inhibition-induced cell death in tamoxifen-resistant cells, likely through lowering endogenous ceramide levels. Our findings suggest that ET-resistant breast cancer cells maintain lower ceramide levels as an essential pro-survival mechanism. Consequently, ET-resistant breast cancer models have a unique dependence on CERK as its activity can inhibit de novo ceramide production.

22 August 2025 in bioRxiv
Verified
Preprint
Open access
PPPurab Pal
Purab Pal
SCShweta Chitkara
Shweta Chitkara
GSGodwin K. Sarpey
Godwin K. Sarpey
FAFatimah Alani
Fatimah Alani
HZHuiping Zhao
Huiping Zhao
JCJonathan Coloff
Jonathan Coloff
Despite the success of endocrine therapy (ET) in treating hormone receptor-positive breast cancer, a significant proportion of patients relapse during or after treatment, making ET resistance a major clinical challenge. Previously we have shown that ET-resistant breast cancer cells exhibit reduced ceramide levels and an increased sensitivity to ceramide-induced cell death. Here, we demonstrate that ceramides induce a distinct transcriptional reprogramming in ET-resistant cells, characterized by upregulation of endoplasmic reticulum stress (EnRS) pathways. Ceramide-induced EnRS is PERK-dependent and functionally linked to cell death in multiple models of ET resistance. Using a photoactivatable ceramide probe, we identify TRAM1 as a functionally important ceramide-interacting protein (CIP) in ET-resistant cells that correlates with worse relapse-free survival and a more aggressive breast cancer phenotype in luminal breast cancer patients. Additionally, knockdown of TRAM1 phenocopies ceramide action in ET resistance, thereby suggesting its role in mediating ceramide-induced lethal actions in ET resistance. Together, our findings reveal that ET-resistant breast cancer cells are more sensitive to PERK-mediated EnRS as compared to their ET-sensitive counterparts. Ceramides can exploit this dependence by interacting with CIPs such as TRAM1, leading to PERK activation and consequential cell death preferentially in the ET-resistant breast cancer models.

1 July 2026 in Molecular Cancer Research
Verified
Journal Article
Open access
PPPurab Pal
Purab Pal
SCShweta Chitkara
Shweta Chitkara
GSGodwin K. Sarpey
Godwin K. Sarpey
AVAanshi Vashi
Aanshi Vashi
VRVipin Rawat
Vipin Rawat
JCJonathan Coloff
Jonathan Coloff
Despite the success of endocrine therapy (ET) in treating hormone receptor–positive breast cancer, a significant proportion of patients relapse during or after treatment, making ET resistance a major clinical challenge. Previously, we have shown that ET-resistant breast cancer cells exhibit reduced ceramide levels and an increased sensitivity to ceramide-induced cell death. In this study, we demonstrate that ceramides induce a distinct transcriptional reprogramming in ET-resistant cells, characterized by upregulation of endoplasmic reticulum stress (EnRS) pathways. Ceramide-induced EnRS is PERK-dependent and functionally linked to cell death in multiple models of ET resistance. Using a photoactivatable ceramide probe, we identify TRAM1 as a functionally important ceramide-interacting protein (CIP) in ET-resistant cells that correlates with worse relapse-free survival and a more aggressive breast cancer phenotype in patients with luminal breast cancer. Additionally, knockdown of TRAM1 phenocopies ceramide action in ET resistance, thereby suggesting its role in mediating ceramide-induced lethal actions in ET resistance. Together, our findings reveal that ET-resistant breast cancer cells are highly sensitive to PERK-mediated EnRS relative to ET-sensitive cells. Ceramides, likely via interactions with CIPs such as TRAM1, lead to PERK activation and consequential cell death in the ET-resistant breast cancer models. This sensitivity to ceramide-induced EnRS and cell death is a vulnerability that could be taken advantage of to treat ET-resistant breast cancer. Implications: This study elucidates the functional relevance of ceramide depletion in ET-resistant breast cancer cells.

2 September 2026
Verified
Other
Open access
PDF file
PPPurab Pal
Purab Pal
SCShweta Chitkara
Shweta Chitkara
GSGodwin K. Sarpey
Godwin K. Sarpey
AVAanshi Vashi
Aanshi Vashi
VRVipin Rawat
Vipin Rawat
JCJonathan Coloff
Jonathan Coloff
Figure S11. TRAM1 as a mediator of ceramide action in ET resistance.

2 September 2026
Verified
Other
Open access
PDF file
PPPurab Pal
Purab Pal
SCShweta Chitkara
Shweta Chitkara
GSGodwin K. Sarpey
Godwin K. Sarpey
AVAanshi Vashi
Aanshi Vashi
VRVipin Rawat
Vipin Rawat
JCJonathan Coloff
Jonathan Coloff
Figure S5. Amino acid starvation of ET-sensitive and -resistant MCF-7 cells.